These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Circulating monoclonal B cells expressing P glycoprotein may be a reservoir of multidrug-resistant disease in multiple myeloma. Pilarski LM; Belch AR Blood; 1994 Feb; 83(3):724-36. PubMed ID: 7507731 [TBL] [Abstract][Full Text] [Related]
5. Multidrug-resistant myeloma: laboratory and clinical effects of verapamil as a chemosensitizer. Salmon SE; Dalton WS; Grogan TM; Plezia P; Lehnert M; Roe DJ; Miller TP Blood; 1991 Jul; 78(1):44-50. PubMed ID: 1676918 [TBL] [Abstract][Full Text] [Related]
6. MDR-1 expression and response to vincristine, doxorubicin, and dexamethasone chemotherapy in multiple myeloma refractory to alkylating agents. Cornelissen JJ; Sonneveld P; Schoester M; Raaijmakers HG; Nieuwenhuis HK; Dekker AW; Lokhorst HM J Clin Oncol; 1994 Jan; 12(1):115-9. PubMed ID: 7903690 [TBL] [Abstract][Full Text] [Related]
7. Expression of MDR1/P-glycoprotein, the multidrug resistance protein MRP, and the lung-resistance protein LRP in multiple myeloma. Schwarzenbach H Med Oncol; 2002; 19(2):87-104. PubMed ID: 12180485 [TBL] [Abstract][Full Text] [Related]
8. Modulation of multidrug-resistant multiple myeloma by cyclosporin. The Leukaemia Group of the EORTC and the HOVON. Sonneveld P; Durie BG; Lokhorst HM; Marie JP; Solbu G; Suciu S; Zittoun R; Löwenberg B; Nooter K Lancet; 1992 Aug; 340(8814):255-9. PubMed ID: 1353189 [TBL] [Abstract][Full Text] [Related]
9. Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. Dalton WS; Grogan TM; Meltzer PS; Scheper RJ; Durie BG; Taylor CW; Miller TP; Salmon SE J Clin Oncol; 1989 Apr; 7(4):415-24. PubMed ID: 2564428 [TBL] [Abstract][Full Text] [Related]
10. Prediction of doxorubicin resistance in vitro in myeloma, lymphoma, and breast cancer by P-glycoprotein staining. Salmon SE; Grogan TM; Miller T; Scheper R; Dalton WS J Natl Cancer Inst; 1989 May; 81(9):696-701. PubMed ID: 2565403 [TBL] [Abstract][Full Text] [Related]
11. Intermittent exposure to doxorubicin in vitro selects for multifactorial non-P-glycoprotein-associated multidrug resistance in RPMI 8226 human myeloma cells. Wyler B; Shao Y; Schneider E; Cianfriglia M; Scheper RJ; Frey BM; Gieseler F; Schmid L; Twentyman PR; Lehnert M Br J Haematol; 1997 Apr; 97(1):65-75. PubMed ID: 9136943 [TBL] [Abstract][Full Text] [Related]
12. Expression of p170 protein in multiple myeloma: a clinical study. Ucci G; Petrini M; Riccardi A; Invernizzi R; Carulli G; Luoni R; Giordano M; Danova M Hematol Oncol; 1992; 10(3-4):213-20. PubMed ID: 1356905 [TBL] [Abstract][Full Text] [Related]
13. Expression of the multidrug resistance P-glycoprotein and its relationship to hematological characteristics and response to treatment in myelodysplastic syndromes. Lepelley P; Soenen V; Preudhomme C; Lai JL; Cosson A; Fenaux P Leukemia; 1994 Jun; 8(6):998-1004. PubMed ID: 7516032 [TBL] [Abstract][Full Text] [Related]
14. Elimination of drug-resistant myeloma tumor cell lines by monoclonal anti-P-glycoprotein antibody and rabbit complement. Kulkarni SS; Wang ZM; Spitzer G; Taha M; Hamada H; Tsuruo T; Dicke KA Blood; 1989 Nov; 74(6):2244-51. PubMed ID: 2572283 [TBL] [Abstract][Full Text] [Related]
15. Cyclosporin A combined with vincristine, doxorubicin and dexamethasone (VAD) compared with VAD alone in patients with advanced refractory multiple myeloma: an EORTC-HOVON randomized phase III study (06914). Sonneveld P; Suciu S; Weijermans P; Beksac M; Neuwirtova R; Solbu G; Lokhorst H; van der Lelie J; Dohner H; Gerhartz H; Segeren CM; Willemze R; Lowenberg B; ; ; Br J Haematol; 2001 Dec; 115(4):895-902. PubMed ID: 11843823 [TBL] [Abstract][Full Text] [Related]
17. Reversal of multidrug resistance by SDZ PSC 833, combined with VAD (vincristine, doxorubicin, dexamethasone) in refractory multiple myeloma. A phase I study. Sonneveld P; Marie JP; Huisman C; Vekhoff A; Schoester M; Faussat AM; van Kapel J; Groenewegen A; Charnick S; Zittoun R; Löwenberg B Leukemia; 1996 Nov; 10(11):1741-50. PubMed ID: 8892677 [TBL] [Abstract][Full Text] [Related]
18. Enhancement by recombinant human interferon alfa of the reversal of multidrug resistance by MRK-16 monoclonal antibody. Fogler WE; Pearson JW; Volker K; Ariyoshi K; Watabe H; Riggs CW; Wiltrout RH; Longo DL J Natl Cancer Inst; 1995 Jan; 87(2):94-104. PubMed ID: 7707396 [TBL] [Abstract][Full Text] [Related]
19. Evidence for a constitutive, verapamil-sensitive, non-P-glycoprotein multidrug resistance phenotype in malignant glioma that is unaltered by radiochemotherapy in vivo. Rieger L; Rieger J; Winter S; Streffer J; Esser P; Dichgans J; Meyermann R; Weller M Acta Neuropathol; 2000 May; 99(5):555-62. PubMed ID: 10805101 [TBL] [Abstract][Full Text] [Related]
20. Common expression of the multidrug resistance marker P-glycoprotein in B-cell chronic lymphocytic leukaemia and correlation with in vitro drug resistance. Sparrow RL; Hall FJ; Siregar H; Van der Weyden MB Leuk Res; 1993 Nov; 17(11):941-7. PubMed ID: 7901453 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]